european_commission_web

Mundipharma’s Neulasta biosimilar approved in EU

pharmafile | November 26, 2018 | News story | Sales and Marketing |  Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma 

Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European Commission.

The decision was driven by a “a robust regulatory submission” of data which supported the biosimilarity of Pelmeg to its reference product, demonstrating non-inferiority in pharmacodynamics, pharmacokinetics, and immunogenicity. It also follows a positive recommendation to approve the product from the Committee for Medicinal Products for Human Use (CHMP). As a result, Pelmeg has been indicated in the exact same way as the subcutaneous form of its reference product, Neulasta.

As a result, Pelmeg will now be available for use to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy, with the exception of chronic myeloid leukaemia and myelodysplastic syndromes.

“We hope this approval will significantly improve the lives of people who are affected by chemotherapy induced neutropenia and febrile neutropenia,” commented Philippe Bastide, Head of Biosimilars at Mundipharma International. “The availability of this biosimilar represents an important opportunity to reduce healthcare costs while increasing access to an effective treatment option.”

Advertisement

Matt Fellows

Related Content

Phoenix Labs acquires Kent Pharma

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content